A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection.
LB-7. Tarek Hassanein1,⇑ Karen D. Sims Michael Bennett Norman Gitlin Eric Lawitz Tuan Nguyen Lynn Webster Zobair Younossi Howard Schwartz Paul J. Thuluvath 11 non-financial support from AbbVie, Achillion, BioCryst, Biotica, Enanta, Gilead Sciences, Idenix, Janssen, Kadmon, Merck, Novartis, Presidio, Santaris, Theravance, and Vertex. L. Webster has received consulting fees from AcelRx, Acura, AstraZeneca, BioDelivery Sciences International, Boehringer Ingelheim, Boston Scientific, and Collegium. Z. Younossi has received consulting fees from Salix, Janssen, Vertex, Gilead Sciences, Enterome, and Coneatus. P.J. Thuluvath has received research grant support from Bristol-Myers Squibb, Gilead Sciences, Vertex, Isai, AbbVie, and Salix, and speaker fees from Gilead Sciences, Onyx, AbbVie, and Bayer. K.D. Sims, B. Rege, N. Zhou, M. Wind-Rotolo, E. Chung, and D.M. Grasela are employees and shareholders of Bristol-Myers Squibb. H. Zhou, F. McPhee, A. Griffies, and D.F. Gardiner are employees of Bristol-Myers Squibb. M. Bennett, N. Gitlin, T. Nguyen, and H. Schwartz have no conflicts of interest to disclose.